NCT05708755PHASE2Recruiting

CMV Immunity Monitoring in Lung Transplant Recipients

NYU Langone Health

Start Date

9/13/2024

Completion Date

5/1/2028

Summary

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

Eligibility Criteria

Age Range: 18 years to 99 years

Inclusion Criteria: 1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health 2. Pre-existing serological immunity to CMV (R+) 3. Able and willing to provide informed consent Exclusion Criteria: 1. Anti-thymocyte globulin induction immunosuppression 2. Perioperative desensitization 3. Pregnant or breastfeeding women

Interventions

DEVICE

Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)

DIAGNOSTIC_TEST

Donor-Derived Cell-Free DNA (dd-cfDNA) Assay

DRUG

Valganciclovir

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lung Transplant; Complications

Locations

NYU Langone Health

New York, New York 10016

United States